Jenny Rooke

Fellow is the only peer-reviewed, clinical semen analysis your patients can do from home. Fellows solutions include: Full Semen Analysis, Post-Vasectomy Semen Analysis , and Cryopreservation. www.meetfellow.com

General Inception is pioneering company creation as the first Igniter company. As an Igniter, General Inception brings a new way to partner with inventors to ignite innovation and nurture transformational companies. General Inception becomes a co-founder and brings together domain expertise, seasoned executive talent, infrastructure resources, and capital to nurture and scale growth throughout the entire company journey.

We use cutting-edge gene editing techniques to develop healthier, hardier and more sustainable crop varieties that flourish even in the face of climate change so local growing communities can thrive, and we can sustain the world’s food supply.

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

Zymergen is now a part of Ginkgo Bioworks!

Zephyrus Biosciences provides research tools to enable protein analysis at the single cell level. Addressing the burgeoning single-cell analysis market, our first product enables western blotting on individual cells for the first time. Researchers will utilize Zephyrus’s products to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development. Zephyrus spun out from Dr. Amy Herr’s laboratory at U.C. Berkeley in 2013 and is affiliated with QB3, BayBio, StartX Med, a Stanford-affiliated nonprofit technology accelerator, and Berkeley Skydeck, the premier accelerator at U.C. Berkeley.

Fellow is the only peer-reviewed, clinical semen analysis your patients can do from home. Fellows solutions include: Full Semen Analysis, Post-Vasectomy Semen Analysis , and Cryopreservation. www.meetfellow.com

General Inception is pioneering company creation as the first Igniter company. As an Igniter, General Inception brings a new way to partner with inventors to ignite innovation and nurture transformational companies. General Inception becomes a co-founder and brings together domain expertise, seasoned executive talent, infrastructure resources, and capital to nurture and scale growth throughout the entire company journey.

We use cutting-edge gene editing techniques to develop healthier, hardier and more sustainable crop varieties that flourish even in the face of climate change so local growing communities can thrive, and we can sustain the world’s food supply.

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.